Navigation Links
New strategies work to put cancer on the firing line
Date:1/2/2008

Dr. Yukai He wants to put cancer in the bulls eye.

Cancer really comes from us, the Medical College of Georgia Cancer Center immunologist says of the scary reality that cancer cells are our own cells gone awry. That means our immune system doesnt always see cancer as a horrific invader.

Tumors and T cells, the cellular arm of the immune system and the main player in anti-tumor immunity, cohabitate for many years before the tumor grows, says Dr. He, who recently was named one of the first Georgia Research Alliance Distinguished Investigators, a new initiative to support outstanding young investigators.

The tumor is smart, he says, changing just enough to stay out of the line of fire.

He and collaborators at Memorial Sloan-Kettering Cancer Center in New York, the University of Chicago and now MCG are putting together a package they believe will place it dead center.

The researchers are packaging an antigen gene that will alert the immune system in a novel viral vector delivery system while quashing the bodys misguided efforts to protect a tumor.

The treatment could one day follow tumor surgery and chemotherapy in patients when recurrence is likely, says Dr. He, who came to MCG in August from the University of Pittsburgh. It also could work for persistent viral infections such as HIV and human papillomavirus, parasitic diseases such as malaria and bacterial infections such as tuberculosis.

It is antigens proteins on or in all cells that get the attention of the immune system. Dendritic cells present antigens to T cells so that the host immune system will be alerted.

Using animal models of melanoma, researchers at Sloan-Kettering are taking key antigens and modifying them just enough to get the attention of T cells but still result in an immune response that targets the cancer.

Dr. He is looking for the best way to deliver modified antigens, identifying which dendritic cells actually present the antigens to T cells, so he can use a delivery mechanism that also gets their attention. Hes using the lentivector, the backbone of HIV minus most of the genes, as the basic mode of transportation. The vector obviously good at getting in and surviving in the body will ideally help generate a potent, memorable immune response that eradicates cancer or an infection in the first place then leaves an immune army waiting should it return.

Vaccination is by far the most effective approach for preventing infectious diseases. These vaccines stimulate B cells to produce antibodies to neutralize targeted bugs. These conventional vaccines are generated by inactivating microbes or attenuating their virulence. For example, the Salk Polio vaccine, first used in the1950s, was made from dead virus, and the Sabin Polio vaccines were from the attenuated virus, in which the infectious part of the virus was inactivated. Scientists next took advantage of the B cells ability to produce antibodies by identifying the most prominent antigen expressed, cloning it and giving it to patients to impart immunity from future infections. Tradeoffs of this type vaccine include a potentially weak immune response since its not the whole virus, but that also means it cant cause disease.

However, some persistent viruses such as HIV and malignant tumor lack a single protein that would inspire sufficient neutralizing antibodies, prompting researchers such as Dr. He to turn to development of T cell vaccines. So far, the most effective and safest way of stimulating T-cell immunity is with recombinant viral vectors, including the lentivector Dr. He is using. Recombinant viral vectors, already under study in HIV vaccine clinical trials, appear safe and effective.

Another important difference from conventional vaccines is that tumor vaccines need to work where tumor growth is established. Tumors impede the work by not just flying under the radar screen but actually suppressing the immune response. Two of Dr. Hes MCG colleagues discovered one of those suppressive mechanisms.

Dr. Andrew Mellor, director of the Immunotherapy Center and Georgia Research Alliance Eminent Scholar in Immunogenetics, and Dr. David Munn, pediatric hematologist-oncologist, showed in work published in 1998 in Science that fetuses use the enzyme IDO indoleamine 2,3-dioxygenase to locally disable a pregnant womans immune system and avoid rejection. Subsequent studies demonstrated that tumors also use IDO for protection by activating regulatory T cells, which has a suppressive effect on the anti-tumor immune response. Hopefully our collaboration will enable a comprehensive treatment package that includes a T cell vaccine and an IDO inhibitor to optimize the therapeutic effect in cancer patients, Dr. He says.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia  
Source:Eurekalert

Related medicine news :

1. A New Interactive Consumer Experience Highlighting Successful Weight Loss Strategies is Coming to a Mall Near You
2. New strategies with greater antitumorous efficacy
3. Eclipsys User Network Brings Eclipsys Clients Together to Share Outcome Improvement Strategies
4. Research suggests targeted treatment strategies for lupus
5. Free White Paper Details Hospital Strategies for Meeting Joint Commission Compliance Requirements in the Environment of Care
6. UCSF launches action tank to advance promising global health strategies
7. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
8. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
9. Survival differences by race most apparent in advanced stages of breast cancer
10. MRI finds breast cancer before it becomes dangerous
11. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New strategies work to put cancer on the firing line
(Date:4/25/2017)... ... , ... Bellus Medical, a leader in medical aesthetics, recently ... of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated ... and minimize the appearance of pores – all with minimal downtime and results ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... ... Lake Park Dental is now accepting new patients with crooked teeth who ... the help of this highly-effective, yet convenient system, patients can straighten their teeth and ... pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America (BPC), ... reputable physician in their area, announces the launch of a new and proprietary customer ... are looking for reputable physicians to help them with back or neck pain and ...
(Date:4/25/2017)... Ariz. (PRWEB) , ... April 25, 2017 , ... Emergency ... latest book of the Outlier Leadership Series, Outliers in Writing, set to publish in ... Professor of Emergency Medicine at the University of Arizona College of Medicine. He also ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WARSAW, Ind. , April 20, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Health Care Conference at the InterContinental Hotel in ... 2017.  Zimmer Biomet will present at 11:20 a.m. Eastern ... can be accessed via Zimmer Biomet,s Investor Relations website ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
Breaking Medicine Technology: